Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer.

Annals of surgical oncology - 1 Jul 2016

Bazzarelli A K, Scheer A S, Tai L H, Seth R, de Souza C Tanese, Petrcich W, Jonker D J, Maroun J A, Carrier M, Auer R C

Abstract excerpt

BACKGROUND: Tissue factor pathway inhibitor (TFPI) is an anticoagulant with antimetastatic properties. The homozygous CC polymorphism of TFPI (-33T → C) is associated with higher TFPI levels and lower venous thromboembolism risk. This study was the first to evaluate the impact of this polymorphism on disease-free survival (DFS) in cancer patients after curative resection. METHODS: A prospectively maintained tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Lipoproteins

Share to Neoplasm Recurrence, Local

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Survival Rate

Source

Identifiers

PMID: 26968713
DOI: 10.1245/s10434-016-5169-4

Genes

TFPI

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer.PMID 26968713Read ↗

Clotting Factor Gene Polymorphisms and Colorectal Cancer RiskSemantic proximity Read ↗

Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients.Semantic proximity Read ↗

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.Semantic proximity Read ↗

Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.Semantic proximity Read ↗

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.Semantic proximity Read ↗

Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.Semantic proximity Read ↗

Genes associated with venous thromboembolism in colorectal cancer patients.Semantic proximity Read ↗

Prothrombin 3'end Gene Variants in Patients With Sporadic Colon Adenocarcinoma.Semantic proximity Read ↗

Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.Semantic proximity Read ↗

The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.Semantic proximity Read ↗

Plasma microRNA Environment Linked to Tissue Factor Pathway and Cancer-Associated Thrombosis: Prognostic Significance in Ovarian CancerSemantic proximity Read ↗

Functional characterization of polymorphisms in the human TFPI gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.